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A non-membrane protein-based nanoparticle agent for the tracking of lipid rafts on live cells 
is produced by stoichiometric functionalization of gold nanoparticles with a previously 
characterized sphingolipid- and cell membrane microdomain-binding domain peptide (SBD). 
The SBD peptide is inserted in a self-assembled monolayer of peptidol and alkane thiol 
ethylene glycol, on gold nanoparticles surface. The stoichiometric functionalization of 
nanoparticles with the SBD peptide, essential for single molecule tracking, is achieved by 
means of non-affinity nanoparticle purification. The SBD-nanoparticles have remarkable 
long-term resistance to electrolyte-induced aggregation and ligand-exchange and have no 
detectable non-specific binding to live cells. Binding and diffusion of SBD-nanoparticles 
bound to the membrane of live cells is measured by real-time photothermal microscopy and 
shows the dynamics of sphingolipid-enriched microdomains on cells membrane, with 
evidence for clustering, splitting and diffusion over time of the SBD-nanoparticle labeled 
membrane domains. The monofunctionalized SBD-nanoparticle is a promising targeting agent 
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for the tracking of lipid rafts independently of their protein composition and the labelling 
requires no prior modification of the cells. This approach has potential for further 
functionalization of the particles to manipulate the organization of, or targeting to 
microdomains that control signaling events and thereby lead to novel diagnostics and 
therapeutics. 
 
1. Introduction 
Lipid rafts are microdomains in the cell membrane with great potential as targets, because of 
their pivotal impact in essential cellular functions. Composed of mixtures of sphingolipids, 
cholesterol and membrane proteins, lipid rafts are dynamic structures with sizes ranging from 
nano- to few micrometers. Since their discovery in 1997,[1] lipid rafts have been investigated 
with the aim of understanding their biological functions and their role in pathologies as 
diverse as cancer and HIV infection. Initially, merely defined from their insolubility property 
in non-ionic detergent, major improvements have been made in the characterization of lipid 
rafts due to the development of techniques in microscopy, lipidomics and proteomics.[2,3] 
Today, it is clear that lipid rafts serve as mobile platforms on cell membranes to bring 
together and assemble functional supramolecular architectures, e.g., protein receptors, to 
activate essential cellular functions such as signal transduction and cell internalization of 
external materials.[4] Moreover, lipid rafts have been recently directly implicated in diseases 
such as the autoimmune skin blistering disease pemphigus vulgaris[5] and Alzheimer’s 
disease.[6] Hence, new tools and the targeting of lipid rafts are essential to improve our 
knowledge of their function and to lead to the development of diagnostics and therapeutics 
aimed at lipid raft functions. 
The targeting of lipid rafts is achieved with biochemical markers that recognize a sub-
component of lipid microdomains present on cells membrane. To date, major efforts have 
been made to target membrane proteins. Glycosylphosphatidylinositol (GPI)-anchored 
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proteins and transmembrane proteins have been used to study the formation and dynamics of 
lipid microdomains by microscopy. Recently, membrane raft association of transmembrane 
proteins has been directly linked to the length of their transmembrane domains and 
palmitoylation.[7] The first methods developed for tracking membrane proteins involved in 
lipid rafts used specific antibodies labelled with fluorescent dyes[5] or loaded on fluorescent 
latex beads.[8] These methods enabled the direct observation of protein partitioning into 
membrane microdomains. Another approach used biotinylated peptide-coated quantum dots 
to track GPI-anchored avidin associated with glycosphingolipid-rich microdomains.[9] 
Similarly, the visualization of the nanoscale distribution and spatial relationship between T-
cell receptor (TCR)/CD3 and co-receptors CD4 or CD8 during the T-cell activation has been 
achieved with near-field scanning optical microscopy and quantum dots coated with 
corresponding antibodies specific to the receptors targeted.[10] 
Since the definition of lipid rafts is through lipids, an approach different from one that is 
membrane protein-based for lipid rafts targeting is to use a biomarker that recognizes lipid 
mixtures that are typical to lipid rafts. Therefore, a non-membrane protein-based lipid raft 
targeting approach is independent of the protein content of lipid rafts present on the cell's 
membrane and so in principle is universal and applicable to all cells with lipid rafts of the 
appropriate composition. The importance of targeting lipids in rafts, rather than proteins, is 
underscored by the recent demonstration that alterations of the lipid composition of rafts 
might be an indicator of early stages of Alzheimer’s disease[11] and some cancers.[12] Hence, a 
targeting agent for lipids that contributes to such lipid rafts has significant potential for the 
development of diagnostics for such diseases. 
The number of existing methods for non-membrane protein-based lipid raft targeting is 
currently limited. Chang et al. used a biotinylated cholera toxin B subunit to label specifically 
the raft constituent ganglioside GM1. Subsequently, the cells were promptly tagged with 
streptavidin conjugated quantum dots to avoid internalization of the biotinylated GM1 and 
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allow confocal microscopy imaging of the lipid rafts.[13] Other pore-forming toxins, e.g., 
ostreolysin A,[14] have been recently reviewed for their potential as lipid raft targeting 
agent.[15] Synthetic lipids functionalized with an affinity group, the tris-nitriloacetic acid (tris-
NTA), were also used to measure the sorting of membrane proteins into lipid ordered and 
disordered lipid phases.[16] Tris-NTA lipids integrated into synthetic membranes and live cells 
were fluorescently tagged with poly-histidine conjugated proteins for single-molecule 
imaging. 
The above represents substantial progress in developing non-membrane protein-based lipid 
rafts targeting methods. Yet, it would be advantageous to use a molecular probe that can bind 
specific lipids and be directly observed in real-time without additional chemical steps or 
modification of the cell membrane. The sphingolipid-binding domain (SBD) peptide is a 25-
peptide sequence of the Alzheimer β-amyloid (Aβ) peptide[17] that binds specifically 
sphingolipid-enriched domains on cell membranes.[18] Fluorescently-labeled SBD peptides 
have been used to track sphingolipid-enriched domains and were shown to interact 
preferentially with raft-like lipid mixtures containing sphingomyelin, cholesterol and 
gangliosides.[19] Recently, the SBD probe offered new insights about lipid raft dynamics and 
their dependence on raft molecular composition.[20,21]  
In this study, we present the preparation of stoichiometrically functionalized SBD-gold 
nanoparticles (SBD-nanoparticles) for the tracking of lipid rafts on live cells. We designed the 
SBD peptide probe for its integration in a peptidol/alkane thiol ethylene glycol self-assembled 
monolayer (Mix-matrix), used to passivate the surface of 8.2 nm diameter gold nanoparticles. 
We stoichiometrically functionalized Mix-matrix capped gold nanoparticles with the SBD 
peptide, essential for single molecule tracking, by a non-affinity based method using ion-
exchange chromatography. Finally, we validated the specific targeting of the 
monofunctionalized SBD-nanoparticles to lipid rafts and observed their dynamics on live 
human SK-N-AS neuroblastoma cells by real-time photothermal microscopy. 
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2. RESULTS AND DISCUSSION 
2.1. Sphingolipid-binding domain peptide ligand design for the functionalization of Mix-
matrix capped gold nanoparticles 
Mixtures of various short thiolated peptidols and alkane thiol ethylene glycols form highly 
stable self-assembled monolayers on the surface of noble metal (gold and silver) 
nanoparticles.[22–24] This approach prevents major biologically-related aggregation, e.g., 
electrolyte-induced aggregation, non-specific binding, ligand exchange, and ensures a high 
biocompatibility,[22–25] while preserving[24] the ease of controlled functionalization found with 
the less stable peptide ligand shells.[25,26] In this study, we used a mixture, so-called Mix-
matrix, of the peptidol, H-CVVVT-ol, and a thiolated alkane ethylene glycol ligand, HS-C11-
EG4, to form a ligand shell for the passivation of 8.2 nm diameter spherical gold nanoparticles 
(Figure S1). We modified the 25-amino acid Aβ-derived SBD peptide in order to facilitate its 
insertion into the Mix-matrix ligand shell (Figure 1). We added a short peptide sequence at 
the N-terminus, H-CVVVT, corresponding to the peptidol present in the Mix-matrix shell to 
ensure its incorporation into the self-assembled monolayer. In addition, we inserted a short 
tetra-ethylene glycol spacer between the SBD and the H-CVVVT sequence, to increase the 
likelihood of the SBD sequence being fully exposed on the surface of the nanoparticles. 
Recently, variations in the fluorescent SBD probe have been investigated to determine 
possible influences of the linker and the overall peptide charge on SBD binding and diffusion 
characteristics.[26] The study showed that a change at position 16 in the 25-amino acid SBD 
peptide from the most common naturally occurring residue in the wild type Aβ sequence of K 
to E, while lowering the pKa, suppressed aggregation, and additionally nuanced its diffusion 
behavior on the cell membrane, making diffusion more homogeneous, i.e., less complex. This 
change in behavior, however, did not in general correlate with the charge of the peptide SBD 
which was modified by either the addition of a C-terminal amide, or the K to E mutation. 
Importantly, a nuclear magnetic resonance study also demonstrated that the substitution of E 
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for K at position 16 does not impair the structure of the Aβ peptide.[27] Moreover, the EG4-
K16-COOH SBD peptide described in the aforementioned study, which contained the wild 
type sequence and is most analogous in construction to the nanoparticle-linked SBD peptide 
used here, displayed similar characteristic confined diffusion behavior typical of SBD and 
other microdomain probes.[18,26,28–30] In fluorescence correlation spectroscopy experiments, it 
also showed approximately the same fraction of probe bound to the cell membrane,[26] and the 
same sensitivity of the slowly-diffusing population to the raft-disrupting agent MβCD as the 
EG4-E16-COOH and the AEEAc-E16-COOH peptides. Together, these observations indicate 
that the K16-containing (wild type, Aβ-identical) 25aa sequence of SBD, while it is likely to 
be more aggregation-prone, behaves similarly as a slowly-diffusing lipid domain marker. 
2.2. Ion-exchange chromatography-based method for purification of stoichiometrically 
functionalized Mix-matrix capped gold nanoparticles with a charged peptide 
The stoichiometric functionalization of nanoparticles generally involves a purification step to 
separate functionalized nanoparticles from non-functionalized nanoparticles. Previously, we 
took advantage of specific affinity, often, but not always from biomolecules, e.g., tris-
NTA/oligo-histidine and FGF-heparin biological affinity.[23,24,31,32] However, a desired 
biofunctionalization may not impart such properties or they may not be easily exploited. This 
is the case with the SBD peptide, where its affinity for sphingolipids cannot be used for the 
purification by chromatography. However, the functionalization may impart a change in 
physicochemical properties of the nanoparticles. In the case of SBD peptide, we took 
advantage of its multiple charged residues to develop a novel method to stoichiometrically 
functionalize Mix-matrix capped gold nanoparticles with the SBD peptide based on ion-
exchange chromatography. 
The method is a straightforward two-step protocol (Figure 2) including a) the surface coating 
of gold nanoparticles with the Mix-matrix peptide ligands, i.e., H-CVVVT-ol and HS-C11-
EG4, and the designed SBD peptide probe, H-CVVVT-EG4-SBD, and b) the separation and 
  
7 
 
purification of monofunctional SBD-nanoparticles by ion-exchange chromatography. The 
SBD-nanoparticles may be then directly used in vitro for the tracking of lipid rafts on live 
cells (Figure 2, c). Interestingly, this non-affinity based method presents the advantages to be 
potentially applicable for other charged biomolecules, e.g., peptides, proteins, DNA, 
oligo/polysaccharides and it provides a strong link between the biomarker and the 
nanoparticle, i.e., a covalent bond, not present, for example in the tris-NTA/oligo-histidine 
conjugation approaches.[24,32] Moreover, this method enables both the purification of 
functionalized charged-biomolecules nanoparticles by removing the functionalized 
nanoparticles from the non-functionalized and the specific preparation of monofunctionalized 
nanoparticles. 
Stoichiometrically functionalized gold nanoparticles with the H-CVVVT-EG4-SBD peptide 
were prepared by coating citrate gold nanoparticles of 8.2 nm diameter (Figure S1) with a 
mixture of H-CVVVT-ol peptidol and HS-C11-EG4 ligands at a molar ratio of 70:30 and an 
additional molar percentage (in place of peptidol) of H-CVVVT-EG4-SBD peptide ligand. 
The SBD ligand was added at a range of mole percentages (from 0 % to 5 %). After coating, 
the excess ligands were removed by centrifugation and size-exclusion chromatography 
(Figure 2, a). In a second stage (Figure 2, b), we used ion-exchange chromatography to isolate 
gold nanoparticles functionalized with charged SBD peptide ligands. The H-CVVVT-EG4-
SBD peptide is negatively charged in 20 mM TRIS buffer at pH 8, because of the acidic side 
chains of the  glutamate and aspartate residues, and the C-terminal carboxylic acid more than 
balancing the basic side chains of the arginine and lysine residues (Figure 1A). The charge of 
the N-terminus amine of the cysteine is not included, because it is adjacent to the gold surface, 
thus it is not exposed to the solvent, as demonstrated previously by the tight packing of the 
Mix-matrix self-assembled monolayer and the absence of charge on Mix-matrix 
nanoparticles.[24] Therefore, the H-CVVVT-EG4-SBD peptide will have a net negative charge, 
and for monofunctionalized nanoparticle (one SBD peptide per nanoparticle) this is likely to 
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be -5 at pH 8 (Figure 1). Each preparation of Mix-matrix capped gold nanoparticles with a 
different range of molar ratio of SBD peptide was purified by ion-exchange chromatography 
with the positively charged diethylaminoethyl (DEAE) Sepharose resin in 20 mM TRIS 
buffer at pH 8. After application of the nanoparticles onto the DEAE column (Figure 2, b-1), 
the non-functionalized nanoparticles were collected in the flow-through fraction, because their 
neutral charge precludes them binding,[24] whereas the negatively charged SBD-nanoparticles 
remained bound to the resin at the top of the column (Figure 2, b-2). SBD-functionalized 
nanoparticles were then eluted from the resin and collected with 1 M NaCl in 20 mM TRIS at 
pH 8.0 (Figure 2, b-3-4). 
The percentage of SBD-nanoparticles immobilized on the DEAE resin, directly linked to the 
percentage of functionalized gold nanoparticles for each preparation,[24,31] was determined by 
comparing the UV-absorbance of the initial mixture of nanoparticles and of the functionalized 
nanoparticles released with the salt solution. A complete range of SBD-nanoparticles 
provided a titration curve (Figure 3). Statistically, a population of stoichiometrically 
functionalized nanoparticles (with no more than 0.48% of that population possessing more 
than one functional ligand) can be prepared when 10 % of the total population of initial 
nanoparticles is functionalized.[24,31] Monofunctionalized SBD-nanoparticles were prepared 
by using 0.5 % of H-CVVVT-EG4-SBD peptide ligand during the coating and purified by 
ion-exchange chromatography. 
2.3. Long-term stability of SBD monofunctionalized Mix-matrix capped gold 
nanoparticles 
The coating of small gold nanoparticles with the Mix-matrix ligand shell, i.e., H-CVVVT-
ol:HS-C11-EG4 (70:30, mole/mole), provides high stability in biological media.[22,24,32] We 
used a previously described normalized aggregation parameter[22] based on UV-visible 
spectrometry to evaluate the colloidal stability of the SBD-nanoparticles overtime against 
electrolyte-induced aggregation and ligand-exchange reaction with a small thiolated molecule, 
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dithiothreitol. SBD-nanoparticles were highly stable against electrolyte-induced aggregation 
in 1 M NaCl at room temperature for over a day, even with a relatively high percentage of 
SBD peptide ligand (1%, Figure S2). Monofunctionalized SBD-nanoparticles were also 
stable in 15 mM DTT in 0.5 M NaCl at room temperature for more than a day (Figure 4). 
Importantly, the high stability of the SBD-nanoparticles ensures their longevity for functional 
raft-tracking even over extended imaging times. 
2.4. Lipid raft tracking with SBD monofunctionalized Mix-matrix capped gold 
nanoparticles by photothermal imaging 
The efficiency of the monofunctionalized SBD-nanoparticles to target lipid rafts was 
evaluated with live human SK-N-AS neuroblastoma cells. We used a homebuilt photothermal 
microscope[33,34] to visualize the SBD-nanoparticles on the cell membrane. After incubation of 
a solution of 125 nM of SBD-nanoparticles with the SK-N-AS cells, unbound nanoparticles 
were washed off before imaging. It was very clear from control experiments that non-
functionalized Mix-matrix capped gold nanoparticles did not have any detectable non-specific 
binding with the cells, with the photothermal signal detected only coming from mitochondria 
under photothermal excitation (Figure 5A), as seen previously with these nanoparticles.[32] 
On the other hand, multiple bright dots were observed when SBD-nanoparticles were 
incubated with the cells, associated with the cell membrane (Figure 5B, white arrows). The 
photothermal peaks observed are significantly higher than the observed background from the 
mitochondrial signal from which they are easily distinguished (Figure 5C). The binding of 
SBD-nanoparticles to the SK-N-AS cells was observed at a lower concentration (125 nM) 
than previously described (5 µM) with a fluorescent tagged SBD, reflecting the differences in 
sensitivity of detection of the nanoparticle versus the fluorophore probes.[19] The analysis of 
the intensity of individual photothermal peaks on the cells, compared to that of individual 
nanoparticles, showed that the former were due to clusters of gold nanoparticles (Figure S3-
S5 and Table S1-S3). By dividing the intensity of the photothermal peaks within the image 
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by the intensity of a single 8.2 nm gold nanoparticle in this system, it was possible to estimate 
the number of SBD-nanoparticles present. The analysis of the photothermal signal intensity 
indicated the presence of multiple SBD-nanoparticles within a diffraction-limited area 
(ranging from 3 nanoparticles up to a peak value in one instance of 270 nanoparticles; Tables 
S1-S3). These may arise through multiple SBD-nanoparticles binding one raft or to multiple 
lipid rafts. It should be noted that the analysis is likely to give an over representation of 
domains with higher numbers of SBD-nanoparticles, as the thresholding used here will 
eliminate peaks whose intensity is very similar to the peak of mitochondrial signals measured 
in unlabeled cells, for example, peaks arising from one or few SBD-nanoparticles. In some 
instances the mitochondrial signal present around the nucleus may have a contributory effect 
to the measured nanoparticle number (peaks marked with an asterisk in Tables S1-S3). 
Interestingly, we observed diffusion of SBD-nanoparticles within the cell membrane. For 
instance, imaging of the same cells over time, i.e., approximately 10 min between images, 
showed obvious movement of multiple nanoparticle clusters, and the appearance of new peaks 
within the same area (Figure 5C and 5D). The movement of putative single SBD-
nanoparticles was also observed, owing to the appearance of “streaks” within the image, and 
correspond to the movement of single nanoparticle labeled lipid rafts parallel to the scan 
direction.[32] The distances observed of clusters travelled when consecutive images were taken 
with 10 min intervals ranged from 1 µm up to more than 10 µm (Figure 5C-5F). During the 
imaging, some movement of SK-N-AS cells on the dish was observed and so this will be 
contributing, in part, to some of the SBD-nanoparticles movement between images. 
The SBD peptide recognizes uniquely lipids such as the sphingolipids sphingomyelin and 
gangliosides that are thought to potentially cluster into domains or lipid rafts,[19,26] and the 
nanoparticles are monofunctionalized with SBD peptide. Therefore, the cell membrane 
association observed with clusters of SBD-nanoparticles, but not with the control non-
functionalized nanoparticles, presumably reflects the interaction of the SBD peptide with its 
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lipid targets in lipid rafts. Moreover, the observed movement of the SBD-nanoparticles within 
one image indicates that the lipid rafts are dynamic. Movement observed between images will 
also reflect the dynamics of lipid rafts, though other factors may contribute on these longer 
timescales, such as cell movement. Thus, photothermal imaging of lipid rafts with 
stoichiometrically functionalized SBD-nanoparticles is a promising route for the quantitative 
analysis of the dynamics of lipid rafts on live cells. 
3. Conclusion 
Lipid rafts are increasingly regarded as membrane structures having an important impact in 
major cellular functions, e.g., cell signaling, internalization of extracellular molecules and 
entities. Moreover, it is now clear that dysfunction of lipid rafts might influence the 
progression of diseases such as various cancers, HIV infection and Alzheimer's disease. 
Although numerous studies report improvements in the characterization of the structure, 
constitution and dynamics of lipid rafts on the cell membrane, there is still an unmet need to 
target lipid rafts without changing or influencing their overall integrity by avoiding chemical 
reactions or genetic mutations of their lipid components. In this study, we developed a 
monofunctionalized SBD-nanoparticle as the first non-membrane protein-based nanoparticle 
targeting agent for lipid raft imaging on live cells. SBD is a unique sphingolipid biomarker, 
and its inclusion into the Mix-matrix self-assembled monolayer enabled the purification of 
stoichiometrically SBD-functionalized gold nanoparticles by ion-exchange chromatography. 
This approach increases the options, hitherto restricted to affinity chromatography, for the 
preparation of stoichiometrically-functionalized nanoparticles; thus ion-exchange 
chromatography selectively removed non-functionalized, and hence non-charged, Mix-matrix 
capped gold nanoparticles and allowed the identification and isolation of nanoparticles 
bearing just one SBD peptide. Interestingly, this method is potentially applicable for the 
stoichiometric functionalization of nanoparticles with a range of other charged biomolecules. 
The monofunctionalized nanoparticles showed long-term high stability against major 
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aggregation factors common in biological media and specific binding to sphingolipid-
enriched microdomains on live cells. The long-term biocompatibility of the SBD-
nanoparticles also enabled their visualization by photothermal imaging of membrane domain 
dynamics with the clustering and mobility of clusters of SBD-nanoparticles over relatively 
long distances, e.g., a few micrometers, over long times. Therefore, the SBD-nanoparticles 
show important potential as non-membrane protein-based lipid raft nanoparticle targeting 
agents to improve our understanding of the biological function of lipid rafts. The ability 
demonstrated here to direct nanoparticles to lipid rafts through their functionalization with the 
SBD peptide also opens the possibility of directing nanoparticles carrying additional functions 
to lipid rafts. Together with the exploitation of the physical properties of the nanoparticle 
itself in photothermal imaging and localized heating of the nanoparticle’s immediate 
environment through the photothermal effect, the SBD-nanoparticles provide the means to 
manipulate cell function at the level of lipid rafts for experimental, and in due course 
therapeutic purposes. Eventually, this knowledge brings hope for the development of novel 
diagnostics and therapeutics by using specific lipid markers as an alternative to the limitations 
of membrane proteins as targets.[12] 
4. Experimental Section 
Materials and chemicals: Peptides H-CVVVT-ol and H-CVVVT-EG4-SBD were purchased 
from Peptide and Protein Research (PPR Ltd., Hampshire, UK). HS-EC11-EG4 ligand was 
purchased from Prochimia (ProChimia Surfaces Sp. z o.o., Sopot, Poland). Gold nanoparticles 
of 8.2 nm diameter stabilized in citrate buffer were purchased from British Biocell 
(BBInternational Ltd., UK). Dimethylsulfoxide (DMSO), methanol, bovine serum albumin 
(BSA) (cat no. 9048-46-8), TRIS buffer pH8 and Tween 20 were purchased from Sigma-
Aldrich Ltd. Nano-sep filters 10 kDa cut off were from PALL (PALL Corp., Portsmouth, 
Hants, UK). Sephadex G25 Fine and diethylaminoethyl (DEAE) Sepharose Fast Flow (GE 
Healthcare) were obtained from SciMed (Asia) Pte Ltd (Singapore). UV spectra were 
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acquired using the Spectra Max Plus spectrophotometer (Molecular Devices, Wokingham, 
UK) and 384 wells plates from Corning (Lowell, US). 
Preparation of SBD functionalized Mix-matrix capped gold nanoparticles: The coating of 
gold nanoparticles with mixtures of peptidol and alkane thiol ethylene glycol ligands was 
done following the method previously published.[22] Briefly, in autoclaved plastic micro-tubes 
or glass containers, 9 volumes of citrate coated gold nanoparticles were added to 1 volume of 
2 mM capping ligands mixture at room temperature. The 2 mM ligand capping mixtures used 
were of ratio 30:70 (mole/mole) of HS-EC11-EG4 to H-CVVVT-ol prepared by dilution of 
fresh stock solutions of ligands at 10 mM in water:DMSO 75:25 (v/v). When functionalized 
nanoparticles were prepared, an additional volume corresponding to the desired percentage of 
2 mM stock solution of the H-CVVVT-EG4-SBD prepared in water:DMSO 75:25 (v/v) was 
introduced in the ligand mixture (100% in Figure 3 corresponding to 1 volume of the capping 
peptidol ligand). After 1 min, the solution was mixed with 1 volume of PBS 10X (81 mM 
Na2HPO4, 12 mM KH2PO4, 1.4 M NaCl, and 27 mM KCl, pH 7.4) and 0.005 volume of a 1% 
(v/v) solution of Tween 20 in milliQ H2O and left on a rotating wheel overnight at room 
temperature. 
The excess of ligands was removed by size-exclusion chromatography (SEC) using Sephadex 
G25 columns with a mobile phase of 100 mM NaCl and 0.002% (v/v) Tween-20. The 
nanoparticle solutions were first concentrated by filtration with Nanosep 10kDa filters to 
obtain a volume of solution equivalent to 5-10% of the total volume of resin in the SEC 
columns. Depending on purification volume, a standard 1.5 cm x 14 cm column (Econo-Pac, 
Bio-Rad Laboratories (Singapore) Pte Ltd.) or XK 26 / XK 50 column (GE Healthcare, 
supplied by SciMed (Asia) Pte Ltd.) were used. Nanoparticles were then exchanged into 20 
mM TRIS buffer pH8 by filtration with Nanosep 10 kDa filters, washing the nanoparticles 
three times with TRIS buffer by centrifugation for 3 min at 12,000 rcf. 
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Purification of SBD functionalized Mix-matrix capped gold nanoparticles by ion-exchange 
chromatography: To a column containing diethylaminoethyl (DEAE) Sepharose Fast Flow 
resin equilibrated in 20 mM TRIS buffer pH8, a volume of functionalized gold nanoparticles 
corresponding to 10% of the total volume of the resin was added. Non-functionalized 
nanoparticles were eluted from the column with 20 mM TRIS, pH8. After complete removal 
of all non-binding nanoparticles, functionalized nanoparticles were released from the resin 
with a 100 mM NaCl and 20mM TRIS, pH8. The solvent of each sample was then exchanged 
by filtration with Nanosep 10kDa filters and washings with PBS buffer pH7.4. 
Photothermal Imaging Set-up: All images were taken using our homebuilt photothermal 
confocal microscope according to the design of Lounis and coworkers.[34,35] The excitation 
laser (532 nm; diode, Ventus Laser Quantum, Germany) was modulated at a frequency of 
459.5 kHz using an acousto-optical modulator (Isomet, UK). This heating beam was then 
‘cleaned’ using a spatial filter, to give the beam a Gaussian profile, and remove ellipticity 
generated by the modulation. The excitation beam was then overlaid with a non-resonant 
probe laser (633 nm; JDSU) via a cold mirror (ThorLabs, Germany). The superimposed 
beams were guided onto the sample via an oil immersion objective (Zeiss Plan-Apochromat 
63x, numerical aperture (NA) 1.4). The sample was held in a fixed position upon a piezo 
scanning stage (MCL 502385, MadCity Labs, WI, USA), which allowed movement of the 
sample in 3 dimensions (x, y, and z) over the fixed laser spot. The scanning was controlled by 
piezo stage driver (MCL NanoDrive 85, Mad City Labs, WI, USA) under the control of the 
Nanonis RC4 module and Nanonis program (Specs Zurich, Germany). All scans were of a 70 
x 70 µm area with a pixel size of approximately 100 nm. The light leaving the sample was 
collected by a second oil objective (Zeiss Neofluar 40x, NA 1.3). This light was passed 
through a high pass filter to remove light arising from the excitation laser, and was focused 
upon one photodiode of a balanced photodiode (Model 2107 10 MHz adjustable 
photoreceiver, New Focus, USA). A lock-in amplifier (DSP 7260, Signal Recovery, IL, USA) 
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was used to identify the scattered component of the probe beam that corresponds to the 
modulation frequency or ‘beat-note’, i.e., 459.5 kHz. The signal was acquired by the Nanonis 
SC4 Acquisition Module. The signal was averaged over a period of 1 ms for most imaging 
applications and a pixel value was generated. The values correspond to the scan path, and 
hence an image of the photothermal signal at each position was generated. The images were 
finally saved in an .sxm format. Raw data files were converted to .txt files using the freeware 
program Gwyddion for analysis. 
Image analysis: Identification of peaks corresponding to nanoparticle labelled sphingolipid 
microdomains was achieved by thresholding the images using ImageJ. Images of labelled 
cells were thresholded with a value equal to that of the peak mitochondrial signals observed in 
unlabeled cells (250 mV). The image was then converted to a binary image and regions of 
interest (ROI) for each detected peak in the image generated. This selection was then applied 
to the original unmodified image, and the maximum intensity of each ROI measured. To 
deduce the approximate number of nanoparticles contributing to the peak, the maximum 
measured photothermal signal values were divided by the value for a single 8.2 nm gold 
nanoparticle. 
Incubation of Neuroblastoma cells with SBD-NPs for photothermal imaging: Human SK-N-
AS neuroblastoma cells (a gift from Anne Hermann, University of Liverpool) were pre-
incubated with 10 mg/mL BSA (Sigma Aldrich, cat no. 9048-46-8) in a buffer that was nine 
parts PBS pH 7.4 (8.1 mM Na2HPO4, 1.2 mM KH2PO4, 140 mM NaCl, and 2.7 mM KCl) to 
one part Krebs Ringer (10 mM Hepes pH 7.4, 140 mM NaCl, 5 mM KCl, 2 mM CaCl2, 2 mM 
MgCl2, and 11 mM glucose) for fifteen minutes. Cells were then washed with PBS and 
incubated with 125 nM SBD-NPs in 10 mg/mL BSA PBS:Ringer for 30 minutes, after which 
the cells were washed three times with 10 mg/mL BSA PBS: Ringer buffer and mounted in 
Krebs Ringer buffer for photothermal imaging. 
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Figure 1. Structure of the SBD peptide. A) The Alzheimer β-amyloid peptide and the 
designed H-CVVVT-EG4-SBD peptide ligand with a K16 mutation. Residues positively and 
negatively charged in solution at pH 8 are highlighted in blue and red, respectively. B) PDB 
structure of the peptide SBD K16. The N-terminus is on the left side of the structure. 
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Figure 2. Preparation of stoichiometrically functionalized gold nanoparticles with a charged 
peptide biomarker. a) Coating and functionalization of gold nanoparticles in solution. b) 
Purification of stoichiometrically functionalized gold nanoparticles by ion-exchange 
chromatography; 1) deposition of nanoparticles mixture; 2) removal of non-functionalized 
nanoparticles; 3) elution and 4) collection of charged functionalized nanoparticles. c) In vitro 
test of stoichiometrically functionalized gold nanoparticles. 
 
 
Figure 3. Titration of functionalization of 8.2 nm Mix-matrix capped gold nanoparticles with 
the sphingolipid-binding domain peptide ligand by ion-exchange chromatography. 
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Figure 4. Ligand-exchange stability test of stoichiometrically functionalized SBD-
nanoparticles. Normalized aggregation parameters after incubation in 0.5 M NaCl and 15 mM 
of DTT at pH 7.4 and room temperature. 
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Figure 5. Photothermal imaging of monofunctionalized SBD nanoparticles labelled 
sphingolipids-enriched microdomains on SK-N-AS cell membranes. A) SK-N-AS cells 
incubated with 125 nM non-functionalized Mix-matrix nanoparticles. B) SK-N-AS cells 
labelled with 125 nM monofunctionalized SBD-nanoparticles. White arrows indicate 
photothermal peaks due to the presence of SBD-nanoparticles. C) Enlarged image 
corresponding to the green box in B). White circles correspond to the initial position of SBD-
nanoparticles photothermal peaks, whereas white rectangles denote movement of single SBD-
nanoparticles. D) Photothermal image of the same area as in C) after 10 min. White circles 
denote the positions of the intense peaks from C). E) Enlarged image from the blue box in B). 
White circles correspond to the initial position of SBD-nanoparticles photothermal peaks and 
white rectangles denote movement of single SBD-nanoparticles during the scan. F) 
Photothermal image of the same area as E) acquired 10 min later. The white circle denotes the 
original position of SBD-nanoparticles in E). Scale bars; A) and B) 10 µm and C) through F) 
4 µm. 
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Figure S1. Sizing of citrate coated spherical gold nanoparticles by high-resolution electronic 
microscopy. The average diameter is 8.2 ± 0.78 nm for 663 counts. 
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Figure S2. Electrolyte-induced aggregation test with 1 M of NaCl solution. Samples of gold 
nanoparticles capped with Mix-matrix prepared with 0, 0.1, 0.2 and 1% of H-CVVVT-EG4-
SBD peptide ligand were evaluated. A value of normalized aggregation parameter of 1 
corresponds to a stable colloidal solution. Here, all samples were stable after two days. 
 
Figure S3. Photothermal Image of SK-N-AS cells labeled with 125 nM SBD-NPs (right). 
Detected sphingolipid microdomains from thresholding analysis are denoted by number in 
blue (left). Scale bar is 10 µm. 
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Figure S4. Photothermal Image of SK-N-AS cells labelled with 125 nM SBD-NPs (right). 
Detected sphingolipid microdomains from thresholding analysis are denoted by number in 
blue (left). Scale bar is 10 µm. 
 
Figure S5. Photothermal Image of SK-N-AS cells labeled with 125 nM SBD-NPs. Detected 
sphingolipid microdomains from thresholding analysis are denoted by number in blue (left). 
Scale bar is 10 µm. 
 
Number of sphingolipids per photothermal peak was calculated by dividing the maximum 
intensity of the photothermal peak by the intensity for a single nanoparticle in this optical 
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system, assuming a 1:1 stoichiometry of sphingolipid to bound nanoparticle. The number is 
then rounded down to the nearest whole nanoparticle. 
 
Table S1. No. Particles per photothermal peak from Figure S3. 
Peak No. Particles Peak No. Particles 
1 85 11* 66 
2 77 12 23 
3 148 13* 49 
4* 49 14* 63 
5 63 15* 16 
6 119 16 73 
7 20 17 46 
8 32 18* 28 
9* 23 19* 18 
10* 59   
* denotes where the mitochondrial background may contribute to the measured and thus 
calculated value.  These peaks correspond to the dashed blue circles within Figure S3. 
 
Table S2. No. Particles per photothermal peak from Figure S4. 
Peak No. Particles Peak No. Particles 
1 126 8* 18 
2* 21 9 24 
3 73 10* 23 
4 21 11 270 
5 98 12 24 
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6 21   
7* 53   
* denotes where the mitochondrial background may contribute to the measured and thus 
calculated value.  These peaks correspond to the dashed blue circles within Figure S4. 
 
Table S3. No. Particles per photothermal peak from Figure S5. 
Peak No. Particles Peak No. Particles 
1 20 32* 41 
2 50 33* 22 
3 62 34 19 
4 23 35* 19 
5 41 36* 36 
6 16 37* 22 
7 29 38* 21 
8 45 39* 39 
9 103 40* 37 
10 27 41 37 
11 24 42 23 
12 27 43* 36 
13* 30 44* 17 
14* 26 45* 21 
15* 29 46* 20 
16* 35 47 3 
17* 27 48* 26 
18* 25 49* 19 
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19* 17 50 56 
20* 27 51* 28 
21 27 52* 22 
22* 18 53* 10 
23* 34 54* 17 
24* 17 55 23 
25* 33 56* 41 
26 40 57* 20 
27* 28 58* 50 
28* 68 59* 21 
29* 28 60 20 
30* 42 61* 19 
31* 43   
 
